4,420 Shares of Becton, Dickinson and Company $BDX Acquired by Capstone Capital Management Ltd

Capstone Capital Management Ltd bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,420 shares of the medical instruments supplier’s stock, valued at approximately $791,000.

Several other large investors have also recently modified their holdings of the business. Pinnacle Associates Ltd. lifted its stake in shares of Becton, Dickinson and Company by 12.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 25,922 shares of the medical instruments supplier’s stock valued at $4,640,000 after buying an additional 2,811 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Becton, Dickinson and Company by 18.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 80,374 shares of the medical instruments supplier’s stock valued at $14,387,000 after acquiring an additional 12,798 shares during the period. Integrated Advisors Network LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth $312,000. Robeco Institutional Asset Management B.V. lifted its position in shares of Becton, Dickinson and Company by 271.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 159,520 shares of the medical instruments supplier’s stock worth $28,554,000 after acquiring an additional 116,612 shares in the last quarter. Finally, Wagner Wealth Management Corp bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $473,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,906 shares of company stock valued at $1,265,855 over the last three months. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $193.77 on Wednesday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $195.99. The stock has a fifty day moving average of $184.51 and a 200 day moving average of $164.26. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a market capitalization of $53.39 billion, a price-to-earnings ratio of 58.36, a P/E/G ratio of 12.86 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company earned $3.68 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BDX shares. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Barclays initiated coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 target price for the company. Piper Sandler upped their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Bank of America upped their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Monday, August 31st. Finally, Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.